Malta - Kiingereza - Medicines Authority

accord healthcare limited - levodopa; carbidopa; entacapone - film-coated tablet - levodopa 100 mg; carbidopa 25 mg; entacapone 200 mg - anti-parkinson drugs

Malta - Kiingereza - Medicines Authority

accord healthcare limited - levodopa; carbidopa; entacapone - film-coated tablet - levodopa 150 mg; carbidopa 37.5 mg; entacapone 200 mg - anti-parkinson drugs

Malta - Kiingereza - Medicines Authority

accord healthcare limited - levodopa; carbidopa; entacapone - film-coated tablet - levodopa 125 mg; carbidopa 31.25 mg; entacapone 200 mg - anti-parkinson drugs

Marekani - Kiingereza - NLM (National Library of Medicine)

avpak - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone 200 mg - entacapone tablets, usp are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with parkinson’s disease (see clinical pharmacology, clinical studies). entacapone tablets, usp effectiveness has not been systematically evaluated in patients with parkinson’s disease who do not experience end-of-dose “wearing-off”. entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.

Marekani - Kiingereza - NLM (National Library of Medicine)

american health packaging - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone 200 mg - entacapone tablets, usp are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with parkinson’s disease (see clinical pharmacology, clinical studies ). entacapone tablets, usp effectiveness has not been systematically evaluated in patients with parkinson’s disease who do not experience end-of-dose “wearing-off”. entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.

Marekani - Kiingereza - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone 200 mg - entacapone tablets are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose "wearing-off" in patients with parkinson's disease (see clinical pharmacology, clinical studies). entacapone tablets' effectiveness has not been systematically evaluated in patients with parkinson's disease who do not experience end-of-dose "wearing-off". entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.

Marekani - Kiingereza - NLM (National Library of Medicine)

wockhardt usa llc. - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone 200 mg - entacapone tablets are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose "wearing-off" in patients with parkinson's disease (see clinical pharmacology, clinical studies). entacapone tablets' effectiveness has not been systematically evaluated in patients with parkinson's disease who do not experience end-of-dose "wearing-off". entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.

Marekani - Kiingereza - NLM (National Library of Medicine)

aurobindo pharma limited - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone 200 mg - entacapone tablets, usp are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with parkinson’s disease (see clinical pharmacology, clinical studies ). entacapone tablets, usp effectiveness has not been systematically evaluated in patients with parkinson’s disease who do not experience end-of-dose “wearing-off”. entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.

Marekani - Kiingereza - NLM (National Library of Medicine)

mylan institutional inc. - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone 200 mg - entacapone tablets are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with parkinson’s disease (see clinical pharmacology, clinical studies). entacapone tablets’ effectiveness has not been systematically evaluated in patients with parkinson’s disease who do not experience end‑of‑dose “wearing-off”. entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.

Marekani - Kiingereza - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone 200 mg - entacapone tablets are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with parkinson’s disease (see clinical pharmacology, clinical studies). entacapone tablets’ effectiveness has not been systematically evaluated in patients with parkinson’s disease who do not experience end-of-dose “wearing-off”. entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.